Particular aspects of platinum compounds used at present in cancer treatment

Critical Reviews in Oncology/Hematology

Volumn 42, Issue 3, 2002, Pages 317-325

  Desoize, Bernard ^a   Madoulet, Claudie ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Anticancer drugs; Carboplatin; Cisplatin; Nedaplatin; Oxaliplatin; Resistance

Indexed keywords

CARBOPLATIN; CISPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELLULAR PARAMETERS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ESOPHAGUS CARCINOMA; HEAD AND NECK CARCINOMA; HISTORY; HUMAN; JAPAN; LUNG CARCINOMA; NONHUMAN; OVARY CARCINOMA; REVIEW; SIDE EFFECT; TESTIS CARCINOMA; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PHARMACOKINETICS; PLATINUM COMPOUNDS;

EID: 0036273687     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00219-0     Document Type: Review

References (56)

1. Inhibition of cell division in Escherichia coli by electrolysis products from platinum electrode
2. Preclinical antitumor evaluation of bis-acetatoamminedichlorocyclohexylamine platinum(IV): An orally active platinum drug
3. In vivo cisplatin-DNA adducts formation and removals as measured with immunochemical techniques
4. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts
5. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo
6. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization
7. Cisplatin and DNA repair in cancer chemotherapy
8. Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II)
9. Oxaliplatin: A review of preclinical and clinical studies
10. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells
11. Anticancer drug resistance and inhibition of apoptosis
12. Preclinical perspectives on platinum resistance
13. Expression of bcl-xL can confer a multidrug resistance phenotype
14. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death
15. Individual dose adaptation of anticancer drugs
16. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function
17. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
18. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
19. Evaluation of two dose individualisation methods for carboplatin
20. Comparison of two dose prediction models for cisplatin
21. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration
22. Resistance to cisplatin
23. Clinical studies of reversal of drug resistance based on glutathione
24. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells
25. Overexpression of metallothionein confers resistance to anticancer drugs
26. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
27. Mechanisms of resistance to cisplatin
28. Glutathione-S-transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma
29. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
30. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II)
31. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
32. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
33. The role of DNA mismatch repair in drug resistance
34. Ongoing and unsaid on oxaliplatin: The hope
35. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA
36. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
37. Cell culture as spheroids: An approach to multicellular resistance
38. Multicellular resistance: A paradigm for clinical resistance?
39. Chemical reactivity of cisplatin bound to human plasma proteins
40. Clinical pharmacokinetics and administration of established platinum drugs
41. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects
42. Clinical pharmacokinetics of oxaliplatin: A critical review
43. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
44. Limited sampling and dose prediction model for cisplatin using a bayesian approach
45. Pharmacokinetics of (glycolate-0,0′)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin
46. In vitro partitioning and biotransformations of oxaloplatin in rat blood and RPMI-1640
47. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
48. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion
49. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update
50. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
51. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
52. Oxaliplatin in practice
53. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice
54. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
55. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
56. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR